** Sarepta would have to conduct new studies to demonstrate the safety of its Duchenne muscular dystrophy therapy, Elevidys, Endpoints News reports, citing a senior FDA official
** "We are looking at all the tools we have" - HHS spokesperson
** Sarepta did not immediately respond to a Reuters request for comment
** Including session's moves, stock down 91.2% YTD
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.